These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32614783)

  • 1. Breast cancer risk based on adapted IBIS prediction model in Slovenian women aged 40-49 years - could it be better?
    Oblak T; Zadnik V; Krajc M; Lokar K; Zgajnar J
    Radiol Oncol; 2020 Jul; 54(3):335-340. PubMed ID: 32614783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer risk prediction using Tyrer-Cuzick algorithm with an 18-SNPs polygenic risk score in a European population with below-average breast cancer incidence.
    Oblak T; Škerl P; Narang BJ; Blagus R; Krajc M; Novaković S; Žgajnar J
    Breast; 2023 Dec; 72():103590. PubMed ID: 37857130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of the IBIS/Tyrer-Cuzick model of breast cancer risk by race and ethnicity in the Women's Health Initiative.
    Kurian AW; Hughes E; Simmons T; Bernhisel R; Probst B; Meek S; Caswell-Jin JL; John EM; Lanchbury JS; Slavin TP; Wagner S; Gutin A; Rohan TE; Shadyab AH; Manson JE; Lane D; Chlebowski RT; Stefanick ML
    Cancer; 2021 Oct; 127(20):3742-3750. PubMed ID: 34228814
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Screening Strategy Modification Based on Personalized Breast Cancer Risk Stratification and its Implementation in the National Guidelines - Pilot Study.
    Krajc M; Gareth Evans D; Blatnik A; Lokar K; Žagar T; Tomšič S; Žgajnar J; Zadnik V
    Zdr Varst; 2020 Dec; 59(4):211-218. PubMed ID: 33133277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance.
    Quante AS; Whittemore AS; Shriver T; Strauch K; Terry MB
    Breast Cancer Res; 2012 Nov; 14(6):R144. PubMed ID: 23127309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 10-year performance of four models of breast cancer risk: a validation study.
    Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
    Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
    Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
    Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
    Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
    J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer risk assessment and risk distribution in 3,491 Slovenian women invited for screening at the age of 50; a population-based cross-sectional study.
    Jarm K; Zadnik V; Birk M; Vrhovec M; Hertl K; Klanecek Z; Studen A; Sval C; Krajc M
    Radiol Oncol; 2023 Sep; 57(3):337-347. PubMed ID: 37665745
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake.
    Kim JO; Schaid DJ; Vachon CM; Cooke A; Couch FJ; Kim CA; Sinnwell JP; Hasadsri L; Stan DL; Goldenberg B; Neal L; Grenier D; Degnim AC; Thicke LA; Pruthi S
    Cancer Prev Res (Phila); 2021 Feb; 14(2):175-184. PubMed ID: 33097489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.
    Ghoncheh M; Ziaee F; Karami M; Poorolajal J
    Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Validation of breast cancer risk assessment tools on a French-Canadian population-based cohort.
    Jantzen R; Payette Y; de Malliard T; Labbé C; Noisel N; Broët P
    BMJ Open; 2021 Apr; 11(4):e045078. PubMed ID: 33846154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme.
    Amir E; Evans DG; Shenton A; Lalloo F; Moran A; Boggis C; Wilson M; Howell A
    J Med Genet; 2003 Nov; 40(11):807-14. PubMed ID: 14627668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the International Breast Cancer Intervention Study (IBIS) model in the High Risk Ontario Breast Screening Program: A retrospective cohort study.
    Brooks JD; Mah A; Christensen RAG; Arneja J; Eisen A; Chiarelli AM
    Genet Med; 2023 Jun; 25(6):100820. PubMed ID: 36919844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial.
    Loehberg CR; Jud SM; Haeberle L; Heusinger K; Dilbat G; Hein A; Rauh C; Dall P; Rix N; Heinrich S; Buchholz S; Lex B; Reichler B; Adamietz B; Schulz-Wendtland R; Beckmann MW; Fasching PA
    Breast Cancer Res Treat; 2010 May; 121(1):101-10. PubMed ID: 20306293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Tyrer-Cuzick (International Breast Cancer Intervention Study) model for breast cancer risk prediction in women with atypical hyperplasia.
    Boughey JC; Hartmann LC; Anderson SS; Degnim AC; Vierkant RA; Reynolds CA; Frost MH; Pankratz VS
    J Clin Oncol; 2010 Aug; 28(22):3591-6. PubMed ID: 20606088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models.
    Laitman Y; Simeonov M; Keinan-Boker L; Liphshitz I; Friedman E
    Genet Res (Camb); 2013 Dec; 95(6):174-7. PubMed ID: 24506973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Receiver Operating Characteristic (ROC) Curve Analysis for Tyrer-Cuzick and Gail in Breast Cancer Screening in Jiangxi Province, China.
    Zhang L; Jie Z; Xu S; Zhang L; Guo X
    Med Sci Monit; 2018 Aug; 24():5528-5532. PubMed ID: 30089770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing breast cancer risk models in Marin County, a population with high rates of delayed childbirth.
    Powell M; Jamshidian F; Cheyne K; Nititham J; Prebil LA; Ereman R
    Clin Breast Cancer; 2014 Jun; 14(3):212-220.e1. PubMed ID: 24461459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An integrated breast cancer risk assessment and management model based on fuzzy cognitive maps.
    Subramanian J; Karmegam A; Papageorgiou E; Papandrianos N; Vasukie A
    Comput Methods Programs Biomed; 2015 Mar; 118(3):280-97. PubMed ID: 25697987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.